Rohto Pharmaceutical (4527) Q1 2025 earnings summary

Executive summary

• Net sales rose 11.8% year-over-year to ¥68,356 million, driven by economic recovery, inbound demand, and yen depreciation.

• Operating profit increased 4.4% year-over-year to ¥11,790 million, while ordinary profit was up 0.3% to ¥12,273 million.

• Net income attributable to owners declined 6.7% year-over-year to ¥8,482 million due to extraordinary losses.

• Comprehensive income rose 17.1% year-over-year to ¥16,071 million, reflecting strong foreign currency translation gains.

• Upward revision of full-year forecast, expecting record-high net sales and profits, and annual dividend increased for the 21st consecutive year.

Financial highlights

• Net sales: ¥68,356 million, up 11.8% year-over-year.

• Operating income: ¥11,790 million, up 4.4% year-over-year.

• Ordinary income: ¥12,273 million, up 0.3% year-over-year.

• Net income attributable to owners: ¥8,482 million, down 6.7% year-over-year due to extraordinary losses.

• Total assets grew to ¥408,731 million, mainly due to increased goodwill and property, plant, and equipment.

Outlook and guidance

• Full-year net sales forecast revised upward to ¥320,000 million, up 18.2% year-over-year.

• Operating income forecast raised to ¥43,200 million, up 7.9% year-over-year.

• Net income forecast to reach ¥32,200 million, up 4.1% year-over-year.

• Acquisitions of Eu Yan Sang International and Mono chem-pharm Produkte reflected from Q3 onward.

• Dividend forecast increased to ¥33.00 per share for the fiscal year.